Loading...
XNAS
MCTA
Market cap445mUSD
Nov 11, Last price  
29.36USD
Name

Charming Medical Ltd

Chart & Performance

D1W1MN
XNAS:MCTA chart
P/E
P/S
EPS
0.08
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
6m
+3.43%
3,530,8226,015,3756,221,751
Net income
1m
+54.16%
-305,117777,8111,199,085
CFO
426k
+44.16%
2,433,803295,429425,888

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating through its subsidiaries and under the Beauty Lab brand in Hong Kong, Charming Medical Limited delivers a comprehensive suite of beauty, wellness, and postpartum services. These services encompass womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox, agarwood moxibustion, TCM-inspired prenatal massages, and Indonesian traditional abdominal binding. In addition to these treatments, the company manufactures and distributes various products. Their product line features TCM-inspired supplements, including the Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets. They also offer beauty products like a ginseng soothing anti-allergy moisturizing wash for various skin issues and solutions for scalp health. The company further provides consultancy services, offering technical training in TCM-inspired therapies and dietary guidance to other well-regarded beauty salons, massage centers, and similar institutions. These services and products are specifically formulated to alleviate premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal symptoms, and concerns related to breast and uterine health. They also contribute to enhancing overall physical strength and balancing endocrine functions, addressing a wide array of common women's health challenges. Charming Medical operates its own network of wellness centers. Founded in 2016, the company maintains its headquarters in Causeway Bay, Hong Kong.
URL
IPO date
Employees
Domiciled in
HK
Incorporated in
VG

Valuation

Title
in thousands, except ratios and share amounts
FYFYFY
2025‑032024‑032023‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT